Streetbeat News

Analyst Ratings

LEA

Wells Fargo analyst Colin Langan has maintained an Equal-Weight rating on Lear Corporation (LEA) and increased the price target from $130 to $134.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:42 pm

ARCB

Stephens & Co. analyst Jack Atkins has maintained an Overweight rating on ArcBest (NASDAQ:ARCB) and increased the price target from $165 to $205.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:42 pm

APTV

Aptiv's stock price is trading lower following a downgrade by Morgan Stanley from Equal-Weight to Underweight, with a reduced price target from $90 to $74.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:42 pm

FI

Stephens & Co. analyst Charles Nabhan has maintained an Equal-Weight rating on Fiserv (NYSE:FI) and increased the price target from $140 to $150.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:38 pm

CCK

Wells Fargo analyst Gabe Hajde maintains an Equal-Weight rating on Crown Holdings (NYSE:CCK) and lowers the price target from $93 to $78.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:36 pm

AZEK

Stephens & Co. analyst Trey Grooms maintains an Overweight rating on AZEK Co (NYSE:AZEK) and raises the price target from $40 to $50.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:36 pm

TENB

Stephens & Co. analyst Brian Colley maintains an Overweight rating on Tenable Holdings (NASDAQ:TENB) and raises the price target from $60 to $62.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:32 pm

CMG

Stephens & Co. analyst Joshua Long has maintained an Overweight rating on Chipotle Mexican Grill (CMG) and increased the price target from $2800 to $3000.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:29 pm

LLY

Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Eli Lilly (LLY) and increased the price target from $700 to $825.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:28 pm

GILD

Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Gilead Sciences (NASDAQ:GILD) but lowered the price target from $90 to $84.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:24 pm